Meeting Announcement – Sofosbuvir

Posted by on October 1, 2013

October 25, 2013 8:00 a.m. to 5:00 p.m.: Antiviral Drugs Advisory Committee Meeting Announcement


Sheraton Silver Spring Hotel

Cypress Ballroom

8777 Georgia Avenue

Silver Spring, Maryland

The committee will discuss new drug application (NDA) 204671, sofosbuvir (an NS5B polymerase inhibitor), manufactured by Gilead Sciences, Inc., with a proposed indication for the treatment of chronic hepatitis C infection, in combination with other agents in adult patients with genotypes 1 to 6 and/or adult patients awaiting liver transplantation.

Please click HERE for the current roster of the Antiviral Drugs Advisory Committee.

ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact


Do you want to find out what happens during this drug’s FDA AdComm meeting? Great news – ISS can help you! Click on the link below in order to receive a summary of this meeting’s outcome!

Drug AdComm Follow-up Request